Integris Medtech IPO

Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments. The company’s business is structured into two core divisions: Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions. Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand. Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors. Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America. As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.

Information on this page is for general awareness only and is not investment advice. Grey market premium (when shown) is unofficial and indicative. Always read the RHP/DRHP and consult a qualified adviser before investing.